Cargando…
Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
BACKGROUND: The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis. METHODS: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420100/ https://www.ncbi.nlm.nih.gov/pubmed/30880918 http://dx.doi.org/10.2147/DDDT.S189156 |
_version_ | 1783404056736169984 |
---|---|
author | Zhou, Tianbiao Lin, Shujun Yang, Shen Lin, Wenshan |
author_facet | Zhou, Tianbiao Lin, Shujun Yang, Shen Lin, Wenshan |
author_sort | Zhou, Tianbiao |
collection | PubMed |
description | BACKGROUND: The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis. METHODS: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and analyzed by meta-analysis. Data on complete remission (CR), total remission (TR; complete plus partial remission), proteinuria levels, urine erythrocyte number, albumin, glomerular filtration rate, negative rate of ds-DNA, C(3) levels, C(4) levels, systemic lupus erythematosus disease activity index (SLE-DAI), etc, were extracted and pooled using RevMan 5.3. RESULTS: In the therapeutic regimen of TAC + glucocorticoids (GC) vs cyclophosphamide (CYC) + GC, the results indicated that the TAC group had high values of CR, TR, albumin, and negative rate of ds-DNA, and low values of proteinuria levels and SLE-DAI when compared with those in CYC group (all P<0.05). In the therapeutic regimen comprising TAC + GC vs mycophenolate mofetil (MMF) + GC, the results indicated that the difference of CR, TR, proteinuria levels, and albumin between TAC group and MMF group were not significant (all P>0.05). In the therapeutic regimen comprising TAC + MMF + GC vs CYC + GC, multitarget therapy group showed higher values of CR, TR, urinary protein decline, and rise of serum albumin when compared with CYC group (all P<0.05). CONCLUSION: TAC is an effective and safe agent in induction therapy of patients with lupus nephritis. |
format | Online Article Text |
id | pubmed-6420100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64201002019-03-16 Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis Zhou, Tianbiao Lin, Shujun Yang, Shen Lin, Wenshan Drug Des Devel Ther Original Research BACKGROUND: The purpose of this study was to detect the efficacy and safety of tacrolimus (TAC) in induction therapy of patients with lupus nephritis. METHODS: Associated studies were extracted from the PubMed and the Cochrane Library on July 10, 2018, and applicable investigations were pooled and analyzed by meta-analysis. Data on complete remission (CR), total remission (TR; complete plus partial remission), proteinuria levels, urine erythrocyte number, albumin, glomerular filtration rate, negative rate of ds-DNA, C(3) levels, C(4) levels, systemic lupus erythematosus disease activity index (SLE-DAI), etc, were extracted and pooled using RevMan 5.3. RESULTS: In the therapeutic regimen of TAC + glucocorticoids (GC) vs cyclophosphamide (CYC) + GC, the results indicated that the TAC group had high values of CR, TR, albumin, and negative rate of ds-DNA, and low values of proteinuria levels and SLE-DAI when compared with those in CYC group (all P<0.05). In the therapeutic regimen comprising TAC + GC vs mycophenolate mofetil (MMF) + GC, the results indicated that the difference of CR, TR, proteinuria levels, and albumin between TAC group and MMF group were not significant (all P>0.05). In the therapeutic regimen comprising TAC + MMF + GC vs CYC + GC, multitarget therapy group showed higher values of CR, TR, urinary protein decline, and rise of serum albumin when compared with CYC group (all P<0.05). CONCLUSION: TAC is an effective and safe agent in induction therapy of patients with lupus nephritis. Dove Medical Press 2019-03-12 /pmc/articles/PMC6420100/ /pubmed/30880918 http://dx.doi.org/10.2147/DDDT.S189156 Text en © 2019 Zhou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zhou, Tianbiao Lin, Shujun Yang, Shen Lin, Wenshan Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis |
title | Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis |
title_full | Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis |
title_fullStr | Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis |
title_full_unstemmed | Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis |
title_short | Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis |
title_sort | efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420100/ https://www.ncbi.nlm.nih.gov/pubmed/30880918 http://dx.doi.org/10.2147/DDDT.S189156 |
work_keys_str_mv | AT zhoutianbiao efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis AT linshujun efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis AT yangshen efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis AT linwenshan efficacyandsafetyoftacrolimusininductiontherapyofpatientswithlupusnephritis |